Drug Discovery Mass Spectrometry Market

The global drug discovery mass spectrometry market is projected to grow from USD 1.05 million in 2025 to USD 1.6 million by 2031, at a CAGR of 8.5% during this period. The market growth is driven by the rapid expansion of the biopharmaceutical developmental pipeline, increasing adoption of high-resolution analytical platforms among & R&D labs, and rising demand for advanced tools that support complex molecular analysis. CRO laboratories are progressively integrating LC-MS, HRMS, and hybrid MS systems to enhance early-stage screening, lead optimization, and biomarker identification, due to their superior accuracy, sensitivity, and structural elucidation capabilities. Growth is further accelerated by the industry’s shift toward precision therapeutics pipeline, large-molecule drug development, and the need for high-throughput, reproducible analytical workflows.

The major players in the drug discovery spectrometry market include Thermo Fisher Scientific (US), Agilent Technologies (US), Waters Corporation (US), Bruker (US), and Shimadzu Corporation (Japan). The competitive landscape involves analyzing the key growth strategies adopted by these major players from 2022 to 2025 to expand their global presence and increase their market share. The primary growth strategies employed by leading companies in this market include product approvals and launches, acquisitions, collaborations, partnerships, and strategic agreements. Over the past three years, product approvals and launches have been the most popular organic growth strategies adopted by market players seeking to increase their share of the market.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific (US) is a global leader in high-resolution mass spectrometry, offering one of the broadest and most advanced portfolios for drug discovery applications. The Orbitrap-based platforms—such as the Q Exactive, Exploris, and Tribrid series are widely used in proteomics, metabolomics, impurity profiling, and structural elucidation due to their superior mass accuracy, resolution, and sensitivity. The company supports critical drug discovery workflows, including biomarker identification, metabolite ID, large-molecule characterization, and quantity, backed by strong software ecosystems and application-ready methods.

Agilent Technologies (US) is a prominent provider of LC-MS platforms that cater to a wide range of drug discovery needs, from routine targeted quantitation to high-resolution untargeted analysis. The company portfolio includes single quadrupole, triple quadrupole, and Q-TOF instruments, along with ion-mobility-enabled systems that enhance structural characterization and molecular profiling. Agilent mass spectrometers are widely adopted in ADME/DMPK studies, impurity characterization, metabolomics, and lead optimization due to their reliability, robustness, and compatibility with flexible workflows that integrate HPLC, UHPLC, and SFC systems. The company focuses on delivering user-friendly software, strong instrument uptime, and scalable solutions that support both early-stage discovery research and regulated bioanalytical environments.

Danaher (US) is a major player in mass spectrometry for drug discovery, known for its strong leadership in quantitative bioanalysis and high-throughput MS workflows. The company provides drug discovery mass spectrometry through its subsidiary SCIEX. The company offers advanced triple quadrupole and QTRAP systems, renowned for their sensitivity, low detection limits, and reproducible quantitation, making them essential in PK/PD, DMPK, and regulated bioanalytical testing. SCIEX emphasizes integrated software, rapid data processing, and workflow automation, making it a preferred choice for pharma labs prioritizing high-speed analysis, precision quantification, and scalable throughput.

Market Ranking:

Leading firms in the market hold a significant share thanks to their technological leadership, a broad range of instruments, and the integration of pharmaceutical and biotechnology workflows. Thermo Fisher Scientific is the market leader, supported by its comprehensive MS platforms (LC, MS, HRMS, Orbitrap), a strong consumables ecosystem, advanced software capabilities, and long-term relationships with large pharma and CROs. Agilent Technologies leverages its leadership in analytical instrumentation, reliable LC and MS systems, and comprehensive workflow solutions, which are widely used in early drug discovery and translational research. Danaher, through SCIEX, is also among the major players, emphasizing high-sensitivity triple quadrupole and QTOF systems, small molecules and biologics analysis, and close collaboration with research institutions. High switching costs, established installed bases, ongoing innovation in sensitivity and throughput, and expanded applications in proteomics and metabolomics benefit these companies, creating high entry barriers and maintaining a competitive environment in the market.

Related Reports:

Drug Discovery Mass Spectrometry Market by Component (Detector, Mass Analyzer, Ion Source, Vacuum System), Product (Triple Quad, Q-ToF, FTMS, Quad, ToF), Application (Biomarker, HTS, Proteomics), Installed Base & Replacement Rate- Global Forecasts to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com